Literature DB >> 10863106

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997).

R N Jones1, M A Croco, K C Kugler, M A Pfaller, M L Beach.   

Abstract

Thirty-seven sentinel hospitals (29 in the United States [US]; eight in Canada) collected bacterial isolates from hospitalized patients with a diagnosis of pneumonia. The antimicrobial susceptibility patterns of these pathogens were determined to more than 60 agents (40 reported) using the reference broth microdilution method described by the National Committee for Clinical Laboratory Standards. The five most frequently recorded species among the 2757 isolates collected during the study were (no. tested/%): Staphylococcus aureus (632/22.9%), Pseudomonas aeruginosa (498/18. 1%), Haemophilus influenzae (284/10.3%), Klebsiella spp. (240/8.7%), and Streptococcus pneumoniae (213/7.7%). There was a significant difference in the susceptibility to antimicrobials between the US and Canada for S. aureus to oxacillin (50.1% versus 93.8% susceptible, respectively), gentamicin (78.7% versus 97.8%), and fluoroquinolones (49.5 to 53.0% versus 89.8 to 94.9%). Amikacin (92. 8% susceptible) was the most active antimicrobial agent against P. aeruginosa, and meropenem was the most potent beta-lactam. Against H. influenzae, most drugs retained a high level of activity, whilst against the S. pneumoniae, only the newer fluoroquinolones (gatifloxacin, levofloxacin, sparfloxacin) remained highly effective in vitro. Only two antimicrobial agents (imipenem and meropenem) were >99% active against the Klebsiella spp. and Enterobacter spp. isolated in this survey (possess extended spectrum beta-lactamases or hyperproduction of Amp C cephalosporins); cefepime (95.6-100.0% susceptible) was significantly more active than other cephalosporins tested. Clonal, epidemic outbreaks of multiply resistant strains were very rare in monitored hospitals. In conclusion, important differences exist between the US and Canada in the susceptibility patterns of some respiratory tract pathogens to commonly used antimicrobial agents with Canadian strains generally being more susceptible to currently available antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10863106     DOI: 10.1016/s0732-8893(00)00115-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  13 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  The Pseudomonas aeruginosa proteome during anaerobic growth.

Authors:  Manhong Wu; Tina Guina; Mitchell Brittnacher; Hai Nguyen; Jimmy Eng; Samuel I Miller
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

Review 3.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.

Authors:  Jane Easton; Stuart Noble; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.

Authors:  Heinz Burgmann; Bernd Mayer; Arno Lukas; Friedrich Kumbein; Rainer Oberbauer
Journal:  Wien Med Wochenschr       Date:  2003

7.  Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.

Authors:  Karri A Bauer; Jessica E West; James M O'Brien; Debra A Goff
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

8.  Isolation and characterisation of KP34--a novel φKMV-like bacteriophage for Klebsiella pneumoniae.

Authors:  Zuzanna Drulis-Kawa; Paweł Mackiewicz; Agata Kęsik-Szeloch; Ewa Maciaszczyk-Dziubinska; Beata Weber-Dąbrowska; Agata Dorotkiewicz-Jach; Daria Augustyniak; Grażyna Majkowska-Skrobek; Tomasz Bocer; Joanna Empel; Andrew M Kropinski
Journal:  Appl Microbiol Biotechnol       Date:  2011-02-16       Impact factor: 4.813

9.  Detection of a highly prevalent and potentially virulent strain of Pseudomonas aeruginosa from nosocomial infections in a medical center.

Authors:  Ghassan M Matar; Mira H Chaar; George F Araj; Zaher Srour; Ghassan Jamaleddine; Usamah Hadi
Journal:  BMC Microbiol       Date:  2005-05-20       Impact factor: 3.605

10.  Caregivers' practices, knowledge and beliefs of antibiotics in paediatric upper respiratory tract infections in Trinidad and Tobago: a cross-sectional study.

Authors:  Neeta Parimi; Lexley M Pinto Pereira; P Prabhakar
Journal:  BMC Fam Pract       Date:  2004-12-01       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.